$6.48
3.28% yesterday
Nasdaq, Mar 31, 10:02 pm CET
ISIN
US92764N1028
Symbol
VIR

Vir Biotechnology Inc Target price 2025 - Analyst rating & recommendation

Vir Biotechnology Inc Classifications & Recommendation:

Buy
78%
Hold
22%

Vir Biotechnology Inc Price Target

Target Price $32.00
Price $6.48
Potential
Number of Estimates 8
8 Analysts have issued a price target Vir Biotechnology Inc 2026 . The average Vir Biotechnology Inc target price is $32.00. This is higher than the current stock price. The highest price target is
$110.00 1,597.53%
register free of charge
, the lowest is .
A rating was issued by 9 analysts: 7 Analysts recommend Vir Biotechnology Inc to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Vir Biotechnology Inc stock has an average upside potential 2026 of . Most analysts recommend the Vir Biotechnology Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 74.21 27.41
13.89% 63.06%
EBITDA Margin -685.70% -1,910.67%
7.89% 178.64%
Net Margin -706.85% -1,751.21%
3.10% 147.75%

8 Analysts have issued a sales forecast Vir Biotechnology Inc 2025 . The average Vir Biotechnology Inc sales estimate is

$27.4m
Unlock
. This is
63.06% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$106m 43.11%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $74.2m 13.89%
2025
$27.4m 63.06%
Unlock
2026
$28.5m 3.79%
Unlock
2027
$64.8m 127.62%
Unlock
2028
$263m 305.72%
Unlock
2029
$745m 183.36%
Unlock

5 Analysts have issued an Vir Biotechnology Inc EBITDA forecast 2025. The average Vir Biotechnology Inc EBITDA estimate is

$-524m
Unlock
. This is
2.94% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-390m 23.42%
Unlock
, the lowest is
$-625m 22.84%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-509m 20.68%
2025
$-524m 2.93%
Unlock
2026
$-545m 4.06%
Unlock
2027
$-539m 1.15%
Unlock
2028
$-315m 41.53%
Unlock
2029
$416m 232.00%
Unlock

EBITDA Margin

2024 -685.70% 7.89%
2025
-1,910.67% 178.64%
Unlock
2026
-1,915.68% 0.26%
Unlock
2027
-831.93% 56.57%
Unlock
2028
-119.89% 85.59%
Unlock
2029
55.85% 146.58%
Unlock

6 Vir Biotechnology Inc Analysts have issued a net profit forecast 2025. The average Vir Biotechnology Inc net profit estimate is

$-480m
Unlock
. This is
8.49% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-441m 15.93%
Unlock
, the lowest is
$-530m 1.05%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-525m 16.56%
2025
$-480m 8.49%
Unlock
2026
$-446m 7.05%
Unlock
2027
$-427m 4.30%
Unlock
2028
$-230m 46.23%
Unlock
2029
$6.9m 102.98%
Unlock

Net Margin

2024 -706.85% 3.10%
2025
-1,751.21% 147.75%
Unlock
2026
-1,568.38% 10.44%
Unlock
2027
-659.41% 57.96%
Unlock
2028
-87.40% 86.75%
Unlock
2029
0.92% 101.05%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -3.83 -3.51
16.56% 8.36%
P/E negative
EV/Sales 0.80

6 Analysts have issued a Vir Biotechnology Inc forecast for earnings per share. The average Vir Biotechnology Inc EPS is

$-3.51
Unlock
. This is
8.36% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-3.22 15.93%
Unlock
, the lowest is
$-3.87 1.04%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-3.83 16.56%
2025
$-3.51 8.36%
Unlock
2026
$-3.26 7.12%
Unlock
2027
$-3.12 4.29%
Unlock
2028
$-1.68 46.15%
Unlock
2029
$0.05 102.98%
Unlock

P/E ratio

Current -1.75 20.09%
2025
-1.91 9.14%
Unlock
2026
-2.06 7.85%
Unlock
2027
-2.15 4.37%
Unlock
2028
-4.00 86.05%
Unlock
2029
134.00 3,450.00%
Unlock

Based on analysts' sales estimates for 2025, the Vir Biotechnology Inc stock is valued at an EV/Sales of

and an P/S ratio of
33.52
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.30 147.62%
2025
0.80 167.77%
Unlock
2026
0.77 3.65%
Unlock
2027
0.34 56.07%
Unlock
2028
0.08 75.35%
Unlock
2029
0.03 64.68%
Unlock

P/S ratio

Current 12.38 21.37%
2025
33.52 170.72%
Unlock
2026
32.30 3.65%
Unlock
2027
14.19 56.07%
Unlock
2028
3.50 75.35%
Unlock
2029
1.23 64.71%
Unlock

Current Vir Biotechnology Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Barclays
Locked
Locked
Locked Feb 28 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 28 2025
Needham
Locked
Locked
Locked Feb 27 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 31 2025
Leerink Partners
Locked
Locked
Locked Jan 13 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 10 2025
JP Morgan
Locked
Locked
Locked Jan 09 2025
Analyst Rating Date
Locked
Barclays:
Locked
Locked
Feb 28 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 28 2025
Locked
Needham:
Locked
Locked
Feb 27 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 31 2025
Locked
Leerink Partners:
Locked
Locked
Jan 13 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 10 2025
Locked
JP Morgan:
Locked
Locked
Jan 09 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today